The role of mitochondria in statin-induced myopathy

European Journal of Clinical Investigation

Volumn 45, Issue 7, 2015, Pages 745-754

  Apostolopoulou, Maria ^a,b   Corsini, Alberto ^c,d   Roden, Michael ^a,b,e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

^e Department of Orthopedic Surgery   (Germany)

Author keywords

Mitochondria; Myopathy; Skeletal muscle; Statins; Ubiquinone

Indexed keywords

ATORVASTATIN; ATROGIN 1; CERIVASTATIN; CHOLESTEROL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOLICHOL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; LIPID; MEVINOLIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PRAVASTATIN; PROTEIN BCL 2; PROTEIN KINASE B; PYRUVIC ACID; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOMATOMEDIN C; UBIDECARENONE; UBIQUINONE;

ARTICLE; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY; CHOLESTEROL SYNTHESIS; DIABETES MELLITUS; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DRUG INDUCED DISEASE; ENERGY METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; GLYCOGEN STORAGE DISEASE TYPE 5; HEART MUSCLE CELL; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPHILICITY; MEDLINE; MELAS SYNDROME; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MUSCLE MITOCHONDRION; MYOPATHY; NONHUMAN; OBESITY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; STATIN INDUCED MYOPATHY; STOMACH ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MUSCLE DISEASE; PHYSIOLOGY; RABBIT; RAT; SKELETAL MUSCLE;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; MUSCULAR DISEASES; RABBITS; RATS; RISK FACTORS; UBIQUINONE;

EID: 84933279969     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12461     Document Type: Article

References (78)

1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.
2. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:Iii39-43.
3. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
4. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10:373-87.
5. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
6. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4-15.
7. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
8. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J 2015;36:1012-22.
9. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7.
10. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418.
11. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care 2013;36(Suppl 2):S325-30.
12. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005;31:572-80.
13. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004;109:Ii34-41.
14. Araki M, Maeda M, Motojima K. Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. Eur J Pharmacol 2012;674:95-103.
15. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis 2009;202:18-28.
16. Siddals KW, Marshman E, Westwood M, Gibson JM. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 2004;279:38353-9.
17. J-i Hanai, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Investig 2007;117:3940-51.
18. Cao P, Hanai J, Tanksale P, Imamura S, Sukhatme VP, Lecker SH. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J 2009;23:2844-54.
19. De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7.
20. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-7.
21. Toyama K, Sugiyama S, Oka H, Iwasaki Y, Sumida H, Tanaka T et al. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis 2011;217:158-64.
22. Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78:60-8.
23. Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013;61:44-53.
24. Schick BA, Laaksonen R, Frohlich JJ, Paiva H, Lehtimaki T, Humphries KH et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007;81:650-3.
25. Miyake Y, Shouzu A, Nishikawa M, Yonemoto T, Shimizu H, Omoto S et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999;49:324-9.
26. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4.
27. Bargossi AM, Grossi G, Fiorella PL, Gaddi A, Di Giulio R, Battino M. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994;15(Suppl):s187-93.
28. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004;94:1306-10.
29. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.
30. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-3.
31. Skarlovnik A, Janic M, Lunder M, Turk M, Sabovic M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit 2014;20:2183-8.
32. Bogsrud MP, Langslet G, Ose L, Arnesen KE, Sm Stuen MC, Malt UF et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand Cardiovasc J 2013;47:80-7.
33. Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008;19:553-7.
34. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed Statin Myopathy. Atherosclerosis 2014;238:329-35.
35. National Clinical Guideline Centre. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: National Clinical Guideline Centre; 2014: 2014.
36. Sugiyama S. HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats. Biochem Mol Biol Int 1998;46:923-31.
37. Hattori T, Saito K, Takemura M, Ito H, Ohta H, Wada H et al. Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment. J Atheroscler Thromb 2009;16:870-7.
38. Nakahara K, Yada T, Kuriyama M, Osame M. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 1994;202:1579-85.
39. Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005;329:1067-75.
40. Pierno S, Camerino GM, Cippone V, Rolland JF, Desaphy JF, De Luca A et al. Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression. Br J Pharmacol 2009;156:1206-15.
41. Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52:198-207.
42. Bouitbir J, Charles AL, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. Eur Heart J 2012;33:1397-407.
43. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006;63:2415-25.
44. Mullen PJ, Zahno A, Lindinger P, Maseneni S, Felser A, Krahenbuhl S et al. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim Biophys Acta 2011;1813:2079-87.
45. Vaughan RA, Garcia-Smith R, Bisoffi M, Conn CA, Trujillo KA. Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis. Eur J Pharmacol 2013;711:1-9.
46. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 1998;152:99-106.
47. Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004;194:10-23.
48. Obayashi H, Nezu Y, Yokota H, Kiyosawa N, Mori K, Maeda N et al. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. J Toxicol Sci 2011;36:445-52.
49. Bouitbir J, Daussin F, Charles AL, Rasseneur L, Dufour S, Richard R et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve 2012;46:367-73.
50. Ranji P, Rauthan M, Pitot C, Pilon M. Loss of HMG-CoA reductase in C. elegans causes defects in protein prenylation and muscle mitochondria. PLoS ONE 2014;9:e100033.
51. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005;62:1709-12.
52. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006;55:551-7.
53. Traustadottir T, Stock AA, Harman SM. High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Age (Dordr) 2008;30:283-91.
54. Wu JS, Buettner C, Smithline H, Ngo LH, Greenman RL. Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve 2011;43:76-81.
55. Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013;62:709-14.
56. Stringer HA, Sohi GK, Maguire JA, Cote HC. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci 2013;325:142-7.
57. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J et al. Effect of statins on skeletal muscle function. Circulation 2013;127:96-103.
58. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5.
59. Gambelli S, Dotti MT, Malandrini A, Mondelli M, Stromillo ML, Gaudiano C et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol 2004;36:85-9.
60. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4.
61. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:92-103.
62. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
63. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.
64. Berta E, Harangi M, Zsiros N, Nagy EV, Paragh G, Bodor M. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. Pharmazie 2014;69:420-3.
65. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis 2007;6:7.
66. Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med 2014;16:810-9.
67. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007;17:695-707.
68. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-62.
69. Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L et al. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 2011;104:167-73.
70. Feng QP, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges, and potential solutions. Pharmacogenomics 2012;13:579-94.
71. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. A case report. Eur Neurol 2007;57:232-5.
72. Szendroedi J, Schmid AI, Meyerspeer M, Cervin C, Kacerovsky M, Smekal G et al. Impaired mitochondrial function and insulin resistance of skeletal muscle in mitochondrial diabetes. Diabetes Care 2009;32:677-9.
73. Tay SK, Dimauro S, Pang AY, Lai PS, Yap HK. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol 2008;39:426-8.
74. Page SR, Yee KC. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Intern Med J 2014;44:690-3.
75. Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis 2014;238:77-82.
76. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32, 225 diabetic and nondiabetic patients. Clin Ther 2007;29:1761-70.
77. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-99.
78. Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Llinares-Garcia D, Muniz-Garcia J, Aldama-Lopez G et al. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transpl Proc 2005;37:4071-3.